Market Overview

Aeterna Zentaris Presents Promising Results for Disorazol Z Cytotoxic Conjugates


Aeterna Zentaris (NASDAQ: AEZS) today presented encouraging
preclinical results for disorazol Z cytotoxic conjugates, such as
AEZS-125, in ovarian cancer. Results showed the compound's high
potential for the treatment of luteinizing hormone-releasing hormone
(LHRH) receptor positive tumors. Data were presented by the Company's
Director of Preclinical Development, Babette Aicher, PhD, during a
poster presentation at the 24th EORTC-NCI-AACR (ENA) Symposium on "Molecular Targets and Cancer
Therapeutics", currently held in Dublin, Ireland. The study is funded
through a grant from the German Ministry of Education and Research.

Juergen Engel, PhD, Aeterna Zentaris President and CEO stated,
"Disorazol Z cytotoxic conjugates such as AEZS-125, are an extension of
our AEZS-108 innovative LHRH receptor targeted platform in oncology.
These encouraging results presented at the ENA Symposium will enable us
to select a specific drug candidate for further preclinical development
expected to start in the first quarter of 2013."


All conjugates of D-Lys6 -LHRH and disorazol Z analyzed, demonstrated high potential
regarding the treatment of LHRH-receptor positive tumors;

For all conjugates, including AEZS-125, proof-of-concept could be
demonstrated in an
LHRH-receptor positive A2780 ovarian cancer xenograft model;

Experiments are currently under way addressing:

Correlation of tumor LHRH-receptor expression and treatment efficacy;


See full press release

Posted-In: News Guidance Management Global


Related Articles (AEZS)

View Comments and Join the Discussion!

Partner Center